Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2017

View Archived Issues

Roche details development of the first V1aR antagonist for social communication deficits in autism

MeiraGTx updates progress of AAV-mediated ocular gene therapy programs

Novel soluble S1P carrier shows efficacy in preclinical models of hypertension and ischemic injury

Long-term cMD1 gene therapy shows efficacy in a canine model of Duchenne muscular dystrophy

FDA approves Kedrab for post-exposure prophylaxis of rabies infection

Actemra approved in Japan for additional indications of Takayasu arteritis and giant cell arteritis

Mavenclad granted European approval for the treatment of highly active relapsing MS

Vimpat approved in Japan as monotherapy for partial onset seizures in patients with epilepsy

Initial clinical experience reported for AZD-5718 in healthy subjects

Treatment begins in phase I/II trial of SB-525 in severe hemophilia A

Yangtze River Pharmaceutical Group and collaborator patent Nav1.7 channel blockers

Fochon Pharma and collaborators present ALK inhibitors

Shenzhen Targetrx Biotechnology divulges novel CYP17A1 inhibitors

AstraZeneca initiates phase I study of AZD-5991 in relapsed or refractory hematologic malignancies

AstraZeneca AB and Eolas Therapeutics patent orexin receptor antagonists

FDA grants breakthrough therapy designation to mogamulizumab for CTCL subtypes

Roche discloses new DDR1 inhibitors

Takeda describes discovery of GPR139 agonist TAK-041 for treating negative schizophrenia symptoms

NantKwest initiates phase I study of haNK in advanced solid tumors

FDA grants priority review to Gazyva sBLA for untreated follicular lymphoma

Janssen reports findings from COMPASS trial of Xarelto in coronary and peripheral artery disease

Philogen subsidiary collaborates with Servier on small molecule discovery

Sanofi completes acquisition of Protein Sciences

Six-month results reported from phase IIb study of GNbAC-1 for relapsing-remitting MS

FDA approves Victoza to reduce risk of major adverse CV events in patients with type 2 diabetes

Xoma licenses gevokizumab commercial rights to Novartis

EMA validates for review MAAs for combination of binimetinib and encorafenib